Louisiana’s Attack on Safe, Telemedicine Abortion Pills Threatens Access Nationwide

Anti-abortion forces in Louisiana have weaponized the courts to try to roll back critical access to mifepristone, the medication used in nearly two-thirds of U.S. abortions and early miscarriage care. Their lawsuit demands that the FDA immediately reinstate a nationwide rule requiring patients to obtain mifepristone in person at a clinic or pharmacy, banning the safer, more accessible option of filling prescriptions by mail or through telemedicine.

This move directly contradicts overwhelming scientific evidence. More than 100 peer-reviewed studies and endorsements from top medical groups like the American Medical Association and the American College of Obstetricians and Gynecologists confirm that mifepristone is safe to dispense remotely. By mid-2025, over one in four abortions in the U.S. were provided via telemedicine, a lifeline for people in rural areas, those with low incomes, survivors of domestic violence, and others for whom traveling to a clinic is a serious barrier.

Despite this, the Trump administration’s FDA is conducting a new review of mifepristone regulations—prompted by a deeply flawed, self-published report from a Project 2025 sponsor known for authoritarian blueprints. This review appears designed to justify more medically unjustified restrictions, undermining decades of evidence-based policy.

On May 1, 2026, the Fifth Circuit court sided with Louisiana, reinstating the in-person dispensing requirement nationwide while the case proceeds. This ruling overrides a lower court’s pause on the case and threatens to force patients—even in states where abortion remains legal—to travel long distances for a pill that experts agree does not require in-person pickup.

The Department of Justice, representing the FDA, has argued the case should be paused because of the ongoing agency review, but notably has not defended the merits of maintaining remote access. This silence speaks volumes about the politicization of the FDA under Trump’s influence.

If Louisiana’s demands succeed, the consequences will be devastating. Patients will face unnecessary burdens and delays, putting their health and autonomy at risk. This fight is not just about one medication—it is about the broader assault on reproductive rights and the weaponization of federal agencies to enforce political agendas.

We will continue to track this case and the Trump administration’s efforts to dismantle safe abortion access through regulatory and legal backdoors. The stakes could not be higher for democracy, health equity, and bodily autonomy.